RT Journal Article
SR Electronic
T1 Potassium hydroxide 5% for the treatment of molluscum contagiosum
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 118
OP 120
DO 10.1136/dtb.2014.10.0285
VO 52
IS 10
YR 2014
UL http://dtb.bmj.com/content/52/10/118.abstract
AB Molluscum contagiosum is a common reason for consultation in primary care. The condition is normally benign and self-limiting1 and the standard advice is to wait for the lesions to resolve spontaneously.2 Recently, potassium hydroxide 5% (MolluDab—Alliance Pharmaceuticals Limited) has been marketed in the UK for the treatment of the condition.3 It is sold as a medical device rather than a licensed medicinal product. Here we consider the evidence for potassium hydroxide 5% in the management of molluscum contagiosum.